UCL Business Ltd
@UCL_Business
UCL Business Ltd (UCLB) is the technology commercialisation company of @ucl | @ucltf fund for UCL academics | member of TenU @TenU_News
609 Following 1.6K Followers
Join us at the @ucl Advanced Therapies Symposium 2025, featuring an unmissable panel discussion on Innovation & Commercialisation, featuring industry and academic leaders.
Book your ticket today! Early bird rates end 28 February. https://t.co/VuXv7rO5Mv
@UCL_Business https://t.co/bUFDVUQRqg
Show more
0
4
2
The winners of the Creating Impact Through Knowledge Exchange Awards 2025 were announced yesterday at Senate House.
It was a fantastic evening which recognised and celebrated knowledge exchange activity across every corner of UCL.
Read the article: https://t.co/zRpLQntAyy https://t.co/0Wy0ocT4At
Show more
3
11
8
Get to know more about UCL spinout @odin_vision, a company developing #AI# software to improve endoscopic procedures for better early detection and diagnosis of cancer.
We recently chatted to Professor @DanStoyanov , Scientific Advisor at Odin, to learn about his experiences of taking his research to market, the impact that the spinout is making, and his advice for aspiring entrepreneurs.
On #WorldCancerDay#, learn about Professor Stoyanov's commercialisation journey: https://t.co/9nd3w5k9rZ
@UCLEnterprise | @uclcs
Show more
0
5
1
Today is #WorldCancerDay# – At UCLB we are so proud of the work our spinouts do to bring hope to millions 👏
Fighting cancer is among medicine’s biggest challenges, and several UCLB spinouts are rising to meet that challenge by bringing to market groundbreaking treatments and diagnostic technologies born out of @ucl research.
📖Read more about the impact these spinouts have in the fight against cancer: https://t.co/F15LzUX7gh
Show more
0
1
0
We’re pleased to be part of the coalition of universities – launched today - calling for more Proof of Concept funding to fuel innovation and economic growth from the commercialisation of university research.
UCLB is proud to have created a £7.5m POC fund which has supported a wide range of early-stage ideas to help them get to an investment-ready stage – as highlighted in today’s opinion piece in Global University Venturing.
📖 Read here: https://t.co/LIVxNRilNp
Show more
0
1
0
🧬 Register Now for the UCL Advanced Therapies Symposium 2025!
Join 250+ experts to explore gene therapy, emerging technologies, rare diseases, and more.
🗓️9 April 2025, 09:00–19:00
📍UCL Great Ormond Street Institute
Book your ticket: https://t.co/VuXv7rODC3
#UCL2025AdvTx# https://t.co/eYAIpbarm7
Show more
0
14
14
Thanks to those who joined us yesterday for another great I/O Lab Coffee Club session with co-founders of UCL spinout Oriole Networks, Professor George Zervas and James Regan.
We look forward to seeing you at the next Coffee Club event 👏
@ucl | @UCLTF | @UCLEngineering | @ucleeenews | @UCLEnterprise
Show more
0
4
0
Last chance to sign up for tomorrow's I/O Lab Coffee Club event.
Join us in conversation with Professor George Zervas (@ucleeenews) and James Regan, co-founders of
@ucl spinout Oriole Networks.
More here ⬇️
Show more
🔊 Calling UCL academics!
Don't miss our next I/O Lab Coffee Club session with Professor George Zervas (UCL's Department of Electronic and Electrical Engineering) and James Regan, co-founders of @ucl spinout Oriole Networks.
Discover more and sign up here: https://t.co/ersYMn6UAi
Show more
0
3
0
Sifted shines a spotlight on the university-affiliated venture funds supporting spinouts, with 92% of the UK’s Russell Group universities now having an affiliated venture fund. @AlbionVC @UCL_Business @Siftedeu
Read more: https://t.co/MFe7DjNtYn
Show more
0
2
1
🔊 Calling UCL academics!
Don't miss our next I/O Lab Coffee Club session with Professor George Zervas (UCL's Department of Electronic and Electrical Engineering) and James Regan, co-founders of @ucl spinout Oriole Networks.
Discover more and sign up here: https://t.co/ersYMn6UAi
Show more
0
4
1
UCLH and GSL’s partnership brings diagnostics hope for Parkinson’s and other diseases 🤝
A new partnership between UCLH and Guilford Street Laboratories (GSL) will combine next generation testing, artificial intelligence, advanced mass spectrometry and machine learning to diagnostics in the UK.
More here: https://t.co/qAF7d9H7Ro
Show more
0
0
0
The @FinancialTimes has run a piece highlighting UCLB spinout Autolus Therapeutics’ journey to produce therapies for cancer side effects 👏
The news story focuses on the work taking place at Autolus’ Stevenage facility, which is manufacturing the latest generation of an innovative, personalised cancer treatment: a new Car-T cell therapy to treat the blood cancer acute lymphoblastic leukaemia.
📖 Read more here: https://t.co/3IBqRtuZsL
Show more
0
2
0
Season’s Greetings from everyone at UCLB!
There have been so many milestone moments in 2024 from our work with UCL’s academic entrepreneurs, where we have continued to bring research and innovations to market to provide a positive real-world impact. We look forward to many more in 2025 and beyond.
Discover some of 2024's highlights: https://t.co/aHMegW3Zrv
Show more
0
0
0
A great end to the year for the EnAcuity team. The UCLB and @imperialcollege spinout has secured £1.28 million pre-seed funding in a round led by Twin Path Ventures, joined by the London Co-Investment Fund and Crista Galli Ventures.
The team are looking to further build and apply EnAcuity’s product, which is the first-ever software-only clinical solution for hyperspectral imaging. @WEISS_UCL @uclcs
#MedTech# #MedicalImaging#
More here: https://t.co/puUCTTpHfz
Show more
0
2
2
In 2024 the Spinout Review anniversary has shown further commitment to nurturing university research and innovation.
Spinouts represent the bridge between groundbreaking research and real-world impact, generating jobs, driving economic growth, and transforming lives.
The Spinout Review has been a landmark moment for the entire tech transfer industry, kicking off a step-change in better deal-making, proliferation of tech transfer clusters and the hardwiring of spinout growth into the UK's industrial strategy.
Find out more about the spinout review here: https://t.co/ZO0QIJi9pu
Show more
0
0
0
It’s been an unforgettable year for Oriole Networks, with the UCLB spinout securing $13m in seed funding to accelerate development of its ‘all-optical’ infrastructure, enabling Large Language Models (LLMs) to be trained up to a hundred times faster with AI inference significantly accelerated, for a fraction of the network power.
Later this year, Oriole raised an additional $22m, taking the total raised this year to $35m.
By 2025, it plans to have its early-stage products in the hands of customers, creating an ecosystem of photonic networking for AI.
Read more: https://t.co/dYj27BEsJQ
Show more
0
3
2
Earlier this year, @UCL spinout company Autolus Therapeutics announced that the U.S. Food and Drug Administration (FDA) had granted marketing approval for AUCATZYL® (obecabtagene autoleucel, obe-cel), for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (r/r B-ALL).
UCLB has supported Autolus in protecting and licensing the obe-cel technology, enabling it to attract further capital to fund its development.
More here: https://t.co/ZXqNNcT9e4
#BioPharm# #TechTransfer# #Spinouts#
Show more
0
0
0
What a year 2024 has been for Trace Neuroscience, with one of the largest biopharma Series A rounds in recent years funding the development of a treatment for amyotrophic lateral sclerosis (ALS), which affects 5000 people in the UK.
UCLB played a crucial role in supporting the intellectual property behind the discovery and facilitating the collaboration between Trace Neuroscience and the academic team at @ucl.
Find out more here: https://t.co/bAQSoCghvl
Show more
0
4
0
